ダウンロード数: 1640
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
57_481.pdf | 1.01 MB | Adobe PDF | 見る/開く |
タイトル: | 内分泌療法抵抗性前立腺癌に対する ドセタキセル療法の治療経験 |
その他のタイトル: | Docetaxel-Based Chemotherapy for Hormone-Refractory Prostate Cancer in Japanese Patients : Experience in a Single Institute |
著者: | 杵渕, 芳明 和食, 正久 鈴木, 中 鶴田, 崇 川口, 研二 |
著者名の別形: | Kinebuchi, Yoshiaki Wajiki, Masahisa Suzuki, Ataru Tsuruta, Takashi Kawaguchi, Kenji |
キーワード: | Hormone-refractory prostate cancer Docetaxel Chemotherapy PSA(prostate specific antigen) |
発行日: | Sep-2011 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 57 |
号: | 9 |
開始ページ: | 481 |
終了ページ: | 486 |
抄録: | Between April 2007 and November 2010, we treated 21 cases of hormone-refractory prostate cancer with docetaxel-based chemotherapy. The administered dose of docetaxel was from 40 to 75 mg/m2, and the treatments were repeated every 3 to 4 weeks. The patients were from 61 to 88 years old (median 78). Fourteen patients were alive, and seven had died. According to the prostate specific antigen response, the complete response rate was 30%, partial response was 10%, no change was 25%, and progressive disease was 25%, respectively. Median time to progression was 7.0 months (from 1 to 43 months), and median overall survival time after chemotherapy was 11.5 months (from 3 to 44 months). One patient died of adverse events. However, in most cases, hematological toxicities were tolerable and manageable, although neutropenia of grade 3 to 4 was observed. On the other hand, non-hematological toxicities that led to discontinuation of the therapy were observed in a few cases. Docetaxel-based chemotherapy was feasible and effective even for patients over 80 years old. In responding cases, it is important to maintain the chemotherapy as long as possible, by modifying the treatment procedures, while paying attention to the adverse events. |
著作権等: | 許諾条件により本文は2012-10-01に公開 |
URI: | http://hdl.handle.net/2433/149240 |
PubMed ID: | 22075607 |
出現コレクション: | Vol.57 No.9 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。